QSAR of phytochemicals for the design of better drugs

Expert Opinion on Drug Discovery

Volumn 7, Issue 10, 2012, Pages 877-902

  Kar, Supratik ^a   Roy, Kunal ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Ethnopharmacology; in silico; Pharmaceuticals; Phytochemicals; QSAR

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; ATROPINE; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DRUG METABOLITE; MORPHINE; PLANT MEDICINAL PRODUCT; QUININE; QUININE DERIVATIVE; SESQUITERPENE LACTONE;

ANIMAL EXPERIMENT; ANIMAL TESTING REDUCTION; BIOLOGICAL ACTIVITY; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; COMPUTER MODEL; COST; DATA BASE; DECISION MAKING; DRUG DESIGN; DRUG INDUSTRY; ETHNOPHARMACOLOGY; HUMAN; LEGAL ASPECT; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

ANIMALS; DATABASES, FACTUAL; DRUG DESIGN; HUMANS; PHYTOTHERAPY; PLANTS, MEDICINAL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866884867     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.716420     Document Type: Review

References (114)

1. Farnsworth NR. Ethnobotany and the Search for New Drugs. Wiley; Chichester: 1994
2. Harvey AL, Waterman PG. The continuing contribution of biodiversity to drug discovery. Curr Opin Drug Discov Dev 1998;1:71-6
3. Cragg GM, Newman DJ, Snader KM. Natural products in drug discovery and development. J Nat Prod 1997;60:52-60
4. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci 2005;78:431-41
5. Hoffman D. The herbal handbook: a user's guide to medical herbalism. Healing Arts Press; Rochester,VT: 1998
6. Harvey A. The continuing value of natural products to drug discovery. GIT Lab J 2001;5(6):284-5
7. Grabley S, Sattler I. Natural products for lead identification: Nature is a valuable resource for providing tools. In: Hillisch A, Hingenfeld R, editors. Modern methods of drug discovery. Birkhäuser Verlag; Switzerland: 2003. p. 87-107
8. Wender PA, Miller BL. Synthesis at the molecular frontier. Nature 2009;460:197-201
9. Patwardhan B, Vaidya ADB, Chorghade M. Reverse pharmacology and systems approaches for drug discovery and development. Curr Bioact Compd 2008;4:201-12
10. Chen K, Baran PS. Total synthesis of eudesmane terpenes by site-selective C-H oxidations. Nature 2009;459:824-8
11. Leonard E, Runguphan W, O'Connor S, et al. Opportunities in metabolic engineering to facilitate scalable alkaloid production. Nat Chem Biol 2009;5:292-300
12. Patwardhan B, Hooper M. Ayurveda and future drug development. J Altern Complement Med 1992;10(12):9-11
13. Lahana R. How many leads from HTS? Drug Discov Today 1999;4:447-8
14. Myers PL. Will combinatorial chemistry deliver real medicines? Curr Opin Biotechnol 1997;8:701-7
15. Patwardhan B, Vaidya ADB, Chorghade M. Ayurveda and natural product drug discovery. Curr Sci 2004;86(6):789-99
16. Cragg GM, Newman DJ. Natural product drug discovery in the next millennium. Pharmaceut Biol 2001;39(Suppl):8-17
17. Holt GA, Chandra A. Herbs in the modern healthcare environment-An overview of uses, legalities, and the role of the healthcare professional. Clin Res Regul Aff (USA) 2002;19:83-107
18. Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep 2000;17:215-34
19. Cane DE. Comprehensive natural products chemistry. Volume 2 Pergamon/Elsevier; Amsterdam: 1999
20. Inturissi CE, Schultz M, Shin S, et al. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci 1983;33:773-6
21. Sneader W. Drug discovery: The evolution of modern medicine. John Wiley & Sons, Inc; New York: 1985. p. 78-80
22. Casy AF, Pariitt RT. Opioid analgesics. Plenum; New York: 1986. p. 407
23. Lomenzo SA, Rhoden JB, Izzenwasser S, et al. Synthesis and biological evaluation of meperidine analogs at monoamine transporters. J Med Chem 2005;48:1336-43
24. Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate [J]. J Am Chem Soc 1996;88:3888
25. Wall ME, Wani MC. Human medicinal agents from plants. American Chemical Society; Washington, DC: 1993. p. 149-69
26. Kingsbury WD, Boehm JC, Jakas DR, et al. Synthesis of water-soluble (aminoalkyl) camptothecin analogs: inhibition of topoisomerase I and antitumor activity. J Med Chem 1991;34:98-107
27. Sawada S, Okajima S, Aiyama R, et al. Synthesis and antitumor activity of 20 (S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10- hydroxycamptothecin. Chem Pharm Bull 1991;39:1446-50
28. Trigg PI. Economic and medicinal plant research. Volume. 3 Academic Press; London: 1989. p. 19-55
29. Tang W, Eisenbrand G. Chinese drugs of plant origin. Springer-Verlag; Berlin: 1992. p. 161-75
30. White AI. Textbook of organic, medicinal and pharmaceutical chemistry. 7th edition. Lippincott JB; Philadelphia: 1977. p. 247-68
31. Coatney GR. Pitfalls in a discovery: the chronicle of chloroquine. Am J Trop Med Hyg 1963;12:121-8
32. Winstanley P, Olliario P. Clinical trials of chemotherpy for falciparum malaria. Expert Opin Invest Drugs 1998;7:261-71
33. Alternative methods in animal experimentation: evaluating scientific, ethical and social issues in the 3Rs context, Final report and recommendations D8. Available from: http://ec.europa.eu/research/biosociety/ pdf/anim-al-see-final-report.pdf [[Last accessed date 14 September 2011]
34. European commission council directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Off J Eur Community 1986;L358:1-29
35. People for the Ethical Treatment of Animals (PETA). Available from: http:// www.peta.org/
36. Selassie CD. History of quantitative structure-activity relationships. In: Abraham DJ, editor. Burger's medicinal chemistry and drug discovery. John Wiley; New York, USA: 2003. p. 1-48
37. Coats EA. QSAR Challenges and Opportunities: A Commentary. Available from: http:/www.netsci.org/Science/ Compchem/feature13.html
38. Kubinyi H. The Quantitative Analysis of Structure-Activity Relationships. In: Wolff ME, editor. Burger's medicinal chemistry and drug discovery. Volume 1 John Wiley & Sons; New York: 1995. p. 497
39. Perkins R, Fang H, Tong W, et al. Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology. Environ Toxicol Chem 2003;22(8):1666-79
40. Snedecor GW, Cochran WG. Statistical methods. Oxford & IBH; New Delhi: 1967
41. He L, Jurs PC. Assessing the reliability of a QSAR model's predictions. J Mol Graph Model 2005;23(6):503-23
42. Ghafourian T, Cronin MTD. The impact of variable selection on the modelling of oestrogenicity. SAR QSAR Environ Sci 2005;16:171-90
43. Roy K, Mitra I, Kar S, et al. Comparative studies on some metrics for external validation of QSPR models. J Chem Inf Model 2012;52:396-408
44. Golbraikh A, Tropsha A. Beware of q2!. J Mol Graph Mod 2002;20(4):269-76
45. Gramatica P. Principles of QSAR models validation: internal and external. QSAR Comb Sci 2007;26:694-701
46. Afantitis A, Melagraki G, Koutentis PA, et al. Ligand-based virtual screening procedure for the prediction and the identification of novel b-amyloid aggregation inhibitors using Kohonen maps and Counterpropagation Artificial Neural Networks. Eur J Med Chem 2011;46:497-508
47. Sahigara F, Mansouri K, Ballabio D, et al. Comparison of different approaches to define the applicability domain of QSAR models. Molecules 2012;17:4791-810
48. Gálvez-Llompart M, Recio MC, García-Domenech R. Topological virtual screening: a way to find new compounds active in ulcerative colitis by inhibiting NF-kB. Mol Divers 2011;15:917-26
49. Prado-Prado FJ, Uriarte E, Borges F, et al. Multi-target spectral moments for QSAR and complex networks study of antibacterial drugs. Eur J Med Chem 2009;44:4516-21
50. Fawcett T. An introduction to ROC analysis. Pattern Recogn Lett 2006;27:861-74
51. Perez-Garrido A, Helguera AM, Borges F, et al. Two new parameters based on distances in a receiver operating characteristic chart for the selection of classification models. J Chem Inf Model 2011;51:2746-59
52. García-March Murcia-Soler M, Pérez-Giménez FFJ, et al. Discrimination and selection of new potential antibacterial compounds using simple topological descriptors. J Mol Graph Model 2003;21:375-90
53. Kristam R, Gillet VJ, Lewis RA, et al. Comparison of conformational analysis techniques to generate pharmacophore hypotheses using catalyst. J Chem Inf Model 2005;45:461-76
54. OECD Document, 2007. Guidance Document on the validation of (Quantitative) 1226 structure-activity relationships (Q)SARs] models, ENV/ JM/MONO(2007)2
55. Mitra I, Saha A, Roy K. Exploring quantitative structure-activity relationship studies of antioxidant phenolic compounds obtained from traditional chinese medicinal plants. Mol Simul 2010;36(13):1067-79
56. Ray S, Sengupta C, Roy K. QSAR modeling of antiradical and antioxidant activities of flavonoids using electrotopological state (E-State) atom parameters. Cent Eur J Chem 2007;5:1094-113
57. Mitra I, Saha A, Roy K. Development of multiple QSAR models for consensus predictions and unified mechanistic interpretations of the free-radical scavenging activities of chromone derivatives. J Mol Model 2012;18:1819-40
58. Mitra I, Saha A, Roy K. In silico development, validation and comparison of predictive QSAR models for lipid peroxidation inhibitory activity of cinnamic acid and caffeic acid derivatives using multiple chemometric and cheminformatics tools. J Mol Model 2012;Published online 21 March 2012;18:3951-67
59. Ray S, Sengupta C, Roy K. QSAR modeling for lipid peroxidation inhibition potential of flavonoids using topological and structural parameters. Cent Eur J Chem 2008;6:267-76
60. Lee K, Jung SW, Naik R, et al. 3D-QSAR study of melanin inhibiting (s)-(+)-decursin and its analogues by pharmacophore mapping bull. Korean Chem Soc 2012;33:149-53
61. Pick A, Müller H, Mayer R, et al. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem 2011;19:2090-102
62. Nicolle E, Boccard J, Guilet D, et al. Breast cancer resistance protein (BCRP/ ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach. Eur J Pharm Sci 2009;38:39-46
63. Salum LB, Dias LC, Andricopulo AD. Fragment-Based QSAR and molecular modeling studies on a series of discodermolide analogs as microtubule- stabilizing anticancer agents. QSAR Comb Sci 2009;28:325-37
64. Schmidt TJ, Heilmann J. Quantitative structure-cytotoxicity relationships of sesquiterpene lactones derived from partial charge (Q)-based fractional Accessible Surface Area Descriptors (Q-frASAs), Quant Struct Act Relat. 2002;21:276-87
65. De-Eknamkul W, Umehara K, Monthakantirat O, et al. QSAR study of natural estrogen-like isoflavonoids and diphenolics from thai medicinal plants. J Mol Graph Model 2011;29:784-94
66. Zhang S, Yang X, Coburn RA, et al. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol 2005;70:627-39
67. Li CL, Chang TT, Sun MF, et al. Structure-based and ligand-based drug design for microsomal prostaglandin E synthase-1 inhibitors, Mol Simulat. 2011;37:226-36
68. Ramírez-Galicia G, Martínez-Pacheco H, Garduño- Juárez R, et al. Exploring QSAR of antiamoebic agents of isolated natural products by MLR, ANN, and RTO. Med Chem Res 2011;Published online 29 September 2011; doi: 10.1007/s00044-011-9767-1
69. Bharate SB, Singh IP. Quantitative structure-activity relationship study of phloroglucinol-terpene adducts as anti-leishmanial agents. Bioorg Med Chem Lett 2011;21:4310-15
70. Bringmann G, Bischof SK, Müller S, et al. QSAR guided synthesis of simplified antiplasmodial analogs of naphthylisoquinoline alkaloids. Eur J Med Chem 2010;45:5370-83
71. Menezes IRA, Lopes JCD, Montanari CA, et al. 3D QSAR studies on binding affinities of coumarin natural products for glycosomal GAPDH of Trypanosoma cruzi. J Comput-Aided Mol Des 2003;17:277-90
72. Dwivedi N, Mishra S, Mishra BN, et al. 3D QSAR Based study of potent growth inhibitors of terpenes as antimycobacterial agents. Open Nutraceuticals J 2011;4:119-24
73. Hemmateenejad B, Javidnia K, Nematollahi M, et al. QSAR Studies on the antiviral compounds of natural origin. J Iran Chem Soc 2009;6:420-35
74. Olivero-Verbel J, Pacheco-Londoño L. Structure-Activity relationships for the Anti-HIV activity of flavonoids. J Chem Inf Comput Sci 2002;42:1241-6
75. Abu-Awwad FM. QSAR Study of the biologically active organosulfurs in natural products. E-J Chem 2010;7(S1):S335-S43
76. Wang Y, Dou J, Cross KP, et al. Computational analysis for hepatic safety signals of constituents present in botanical extracts widely used by women in the united states for treatment of menopausal symptoms. Regul Toxicol Pharmacol 2011;59:111-24
77. Gavernet L, Talevi A, Castro EA, et al. A Combined virtual screening 2D and 3D QSAR methodology for the selection of new anticonvulsant candidates from a natural product library. QSAR comb. Sci 2008;27:1120-9
78. Scotti L, Scotti MT, Ishiki HM, et al. Quantitative elucidation of the structure-bitterness relationship of cynaropicrin and grosheimin derivatives. Food Chem 2007;105:77-83
79. Zaheer-ul-Haq Wellenzohn B, Tonmunphean S, et al. 3D-QSAR Studies on natural acetylcholinesterase inhibitors of Sarcococca saligna by Comparative Molecular Field Analysis (CoMFA). Bioorg Med Chem Lett 2003;13:4375-80
80. Fassihi A, Sabet R. QSAR Study of p56lck Protein tyrosine kinase inhibitory activity of flavonoid derivatives using MLR and GA-PLS. Int J Mol Sci 2008;9:1876-92
81. Joshi P, Tanwar O, Rambhade S, et al. 2-D QSAR studies of steroidal natural products oleanic acid and their semisynthetic derivatives as potent protein tyrosine phosphatase 1B inhibitors. Med Chem Res 2012;21:351-61
82. Available from: http://www.herbalgram. org
83. Available from: http://www. americanherbalistsguild.com/
84. Available from: http://www.biosis.org
85. Available from: http://www. naturalproducts-niper.com/ NorthEastBooks.aspx
86. Available from: http://www.nybg.org/ bsci/spub/botr/frntpg3b.html
87. Available from: http://www.nrc.ca/cgibin/ cisti/journals/rp/rp2-desc-e? cjb
88. Available from: http://www.herbalists.on. ca/journal/
89. Available from: http://www.cas.org/
90. Available from: http://www.ars-grin.gov/ duke
91. Available from: http://www.econbot.org
92. Available from: http://thoth.library.utah. edu:1701/primo-library/libweb/ action/ dlDisplay.do?vid=UUU&docId= uuu-aleph000074757&fromSitemap= 1&afterPDS=true
93. Available from: https://secure.fera.defra. gov.uk/treechemicals/
94. Available from: http://www.herbs.org
95. Available from: http://www. botanicalmedicine.org
96. Available from: http://www.herbmed.org/
97. Available from: http://www. herbquarterly.com
98. Available from: http://www.harcourtinternational. com/journals/ijar
99. Available from: http://www.iherb.org
100. Available from: http://info.cas.org/ ONLINE/DBSS/ipass.html.
101. Available from: http://www.elsevier.com/ locate/jethpharm
102. Available from: http://pubs.acs.org/ journals/jnprdf/index.html
103. Available from: http://www.nlm.nih.gov/ medlineplus/alternativemedicine. html
104. Available from: http://medherb.com/ MHHOME.SHTML
105. Available from: http://www.nlm.nih.gov/
106. Available from: http://www.tandf.co.uk/ journals/titles/10575634.html
107. Available from: http://www.rsc.org/is/ journals/current/npr/nprpub.htm
108. Available from: http://nccam.nih.gov/ health/herbsataglance.htm
109. Available from: http://tcm.cmu.edu.tw/
110. Available from: http://www.ornl.gov/ TechResources/tirc/hmepg.html
111. Available from: http://www.elsevier.com/ locate/toxicon
112. Available from: http://toxnet.nlm.nih. gov/cgi-bin/sis/htmlgen?TOXLINE
113. Available from: http://www.ars.usda.gov/ main/site-main.htm?modecode=12- 35- 45-00
114. Available from: http://www.leffingwell. com/plants.htm